Verastem, Inc.: directors' dealings · United States · SEC (Form 4)

About Verastem, Inc.

Verastem, Inc. (ticker: VSTM) is a United States-listed biopharmaceutical company trading on NASDAQ. For French, Belgian, and Swiss investors, Verastem is best understood as a specialty oncology company focused on precision medicines for cancers driven by the RAS/MAPK pathway. Founded in 2010 and historically based in the Boston/Needham, Massachusetts area of the United States, the company has pursued a highly targeted model: develop drugs for molecularly defined patient subsets where treatment options remain limited. Compared with large diversified pharmaceutical groups, Verastem is a much narrower, development-heavy biotech with an emerging commercial footprint. The company’s business is currently centered on two main pillars. First, Verastem markets AVMAPKI FAKZYNJA CO-PACK, which received FDA approval in May 2025 for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer. That approval is strategically important because it gave the company its first commercial oncology product in a rare disease setting and created a new revenue base. Second, Verastem is advancing a pipeline led by VS-7375, an oral KRAS G12D (ON/OFF) inhibitor. The program has produced encouraging early clinical data and has received supportive regulatory momentum, including Fast Track designation. The company also continues to build on a broader scientific strategy around combination regimens designed to overcome pathway resistance in solid tumors, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer. From a competitive standpoint, Verastem is positioned as a focused precision-oncology player. Its niche is attractive because KRAS-driven cancers represent a biologically validated opportunity, but the field is highly competitive, with major pharmaceutical companies and better-capitalized biotechs all pursuing related pathways. Verastem’s differentiation lies in its specialization, its clinical execution in rare tumors, and its early commercial entry in low-grade serous ovarian cancer. Geographic presence remains primarily in the United States, although some clinical development and research collaborations are international. Recent milestones are material for investors: FDA approval in May 2025, the launch of commercialization for AVMAPKI FAKZYNJA CO-PACK, publication of clinical and translational data in leading journals, and a portfolio shift toward VS-7375 after discontinuing the RAMP 203 KRAS G12C trial to reallocate resources. Overall, Verastem remains a small-cap biotechnology name with meaningful catalyst potential, but also the typical volatility and execution risk associated with oncology development and early-stage commercialization.